
The first generation of clinically useful zzso agents focused on zzso and targets in the zzso zzso The strengths and limitations of these zzso are now zzso Some tumors do not respond to zzso therapies de zzso and others become zzso or resistant over time by switching to other zzso zzso The next generation of zzso zzso will expand the field beyond the zzso zzso and become more disease zzso zzso growth factor, a protein closely related to zzso is induced as tumors lose responsiveness to zzso zzso zzso 1 and 2 are being targeted with a unique zzso a human zzso zzso constant region fused to zzso in clinical zzso The zzso zzso is zzso in some tumors as an alternate zzso zzso The zzso zzso zzso represents a zzso zzso axis involved in tumor zzso zzso is a zzso coupled zzso with several zzso including zzso and other zzso zzso and may represent a useful target for zzso zzso The notch zzso is being investigated as a target in the setting of tumor zzso zzso is a zzso zzso that can be neutralized with a zzso zzso The zzso zzso is under investigation as an zzso zzso Finally, several zzso zzso zzso each with a unique pattern of zzso potency are in clinical trial with a focus on zzso zzso The expansion of the scope of potential zzso agents in or entering clinical trial should allow the development of zzso combination regimens and single agents that address diseases zzso to zzso zzso 

